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Endothelial dysfunction is a characteristic feature in diabetes that contributes to the devel-
opment of vascular disease. Recently, arginase has been implicated in triggering endothelial
dysfunction in diabetic patients and animals by competing with endothelial nitric oxide syn-
thase for substrate L-arginine.While most studies have focused on the coronary circulation
and large conduit blood vessels, the role of arginase in mediating diabetic endothelial dys-
function in other vascular beds has not been fully investigated. In the present study, we
determined whether arginase contributes to endothelial dysfunction in skeletal muscle
arterioles of diabetic rats. Diabetes was induced in male Sprague Dawley rats by strepto-
zotocin injection. Four weeks after streptozotocin administration, blood glucose, glycated
hemoglobin, and vascular arginase activity were significantly increased. In addition, a sig-
nificant increase in arginase I and II mRNA expression was detected in gracilis muscle
arterioles of diabetic rats compared to age-matched, vehicle control animals. To exam-
ine endothelial function, first-order gracilis muscle arterioles were isolated, cannulated
in a pressure myograph system, exposed to graded levels of luminal flow, and internal
vessel diameter measured. Increases in luminal flow (0–50µL/min) caused progressive
vasodilation in arterioles isolated from control, normoglycemic animals. However, flow-
induced vasodilation was absent in arterioles obtained from streptozotocin-treated rats.
Acute in vitro pretreatment of blood vessels with the arginase inhibitors Nω-hydroxy-nor-
L-arginine or S-(2-boronoethyl)-L-cysteine restored flow-induced responses in arterioles
from diabetic rats and abolished differences between diabetic and control animals. Sim-
ilarly, acute in vitro pretreatment with L-arginine returned flow-mediated vasodilation in
vessels from diabetic animals to that of control rats. In contrast, D-arginine failed to restore
flow-induced dilation in arterioles isolated from diabetic animals. Administration of sodium
nitroprusside resulted in a similar degree of dilation in arterioles isolated from control or
diabetic rats. In conclusion, the present study identifies arginase as an essential media-
tor of skeletal muscle arteriolar endothelial dysfunction in diabetes. The ability of arginase
to induce endothelial dysfunction in skeletal muscle arterioles may further compromise
glucose utilization and facilitate the development of hypertension in diabetes.
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INTRODUCTION
Diabetes is a progressive metabolic disease that is characterized
by an elevation in circulating glucose related to either insulin
deficiency (type 1 diabetes) or insulin resistance (type 2 dia-
betes). Diabetes and its associated complications are a growing
concern and represent a serious worldwide public health prob-
lem. Vascular disease is the principal cause of morbidity and
mortality in patients with diabetes (Kannel and McGee, 1979;
Winer and Sowers, 2004). Accelerated atherosclerosis of the large
arteries results in increased risk of myocardial infarction, stroke,
and limb amputation while microvascular disease is a leading
cause of blindness, nephropathy, and neuropathy (Beckman et al.,
2002; Porta and Bandello, 2002; Goldberg, 2003; Kikkawa et al.,
2003; Duby et al., 2004). Abnormal endothelial function is a
salient feature of vascular disease in diabetes that is exemplified
by a decrease in nitric oxide (NO) synthesis or bioavailability.
In response to shear stress or receptor stimulation, NO is pro-
duced by endothelial NO synthase (eNOS) through the oxidation
of its substrate, l-arginine. The release of NO by endothelial
cells plays a critical role in preserving vascular homeostasis by
inhibiting vascular tone, platelet aggregation, leukocyte recruit-
ment and infiltration into the vessel wall, and smooth muscle
cell proliferation and migration (see Loscalzo and Welch, 1995;
Forstermann and Sessa, 2012). Endothelial dysfunction, including
blunted NO-dependent vasodilatory responses, has been docu-
mented in patients and animals with diabetes, and is believed
to be an important contributor to the pathogenesis of dia-
betic vascular disease (Durante et al., 1988; Hattori et al., 1991;
Tesfamariam and Cohen, 1992; Johnson et al., 1993; Nitenberg
et al., 1993).
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Although many factors have been implicated in triggering
endothelial malfunction, recent studies have identified arginase
as a novel mediator of endothelial dysfunction. Arginase is a met-
alloenzyme that hydrolyzes l-arginine to urea and l-ornithine.
There are two distinct isoforms of arginase, arginase I and II,
which are encoded by separate genes and share approximately
60% sequence homology (Dizikes et al., 1986; Vockley et al.,
1996). Both isoforms of arginase are expressed in the vascula-
ture but their expression is both vessel- and species-dependent
(see Durante et al., 2007; Morris, 2009). Arginase elicits endothe-
lial dysfunction by competing with eNOS for substrate l-arginine
leading to a deficiency of l-arginine and diminished NO synthe-
sis. Recent work from a number of laboratories has implicated
arginase in provoking endothelial dysfunction in several patho-
logical states, including arterial hypertension, pulmonary hyper-
tension, atherosclerosis, aging, and hemorrhagic shock (Xu et al.,
2004; Demougeot et al., 2005; Johnson et al., 2005,2010; Ryoo et al.,
2008; Kim et al., 2009). In a seminal study, Romero et al. (2008)
demonstrated increased vascular arginase I expression and activ-
ity in streptozotocin-treated rats and that arginase contributes to
endothelial dysfunction in coronary arteries in this animal model
of type 1 diabetes. In addition, it was found that arginase stimu-
lates endothelial dysfunction in myocardial microvessels in type 2
diabetic rats and in coronary arterioles isolated from patients with
type 2 diabetes (Beleznai et al., 2011; Gronros et al., 2011). Subse-
quently, arginase was also shown to impair endothelial function in
the aorta, retinal arteries, and corpora cavernosa of streptozotocin-
induced type 1 diabetic animals (Toque et al., 2011; El-Bassossy
et al., 2012; Romero et al., 2012; Elms et al., 2013). However, the
involvement of arginase in mediating endothelial dysfunction in
other vascular beds of diabetic animals is not known.
A majority of the studies examining the contribution of
arginase to endothelial dysfunction in diabetes utilize acetyl-
choline to test the vasoactive function of the endothelium. How-
ever, a physiological role for acetylcholine in the local regulation
of vascular resistance has not been established. Furthermore, in
many vascular beds a large portion of acetylcholine-mediated
vasodilation is NO-independent (Bolz et al., 1999). Thus, the use
of acetylcholine may not fully reveal the nature and physiologic
importance of endothelial dysfunction in diabetes. A major in vivo
stimulus for the synthesis and release of NO by endothelial cells
is luminal flow which functions to continuously modulate arte-
rial diameter via changes in shear stress. In order to more fully
evaluate the role of arginase in promoting endothelial dysfunc-
tion in type 1 diabetes, we determined the expression of arginase
I and II in skeletal muscle arterioles in rats treated with streptozo-
tocin or vehicle. In addition, we examined endothelial function in
these arterioles in response to a highly relevant physiologic stim-
ulus: luminal flow. Finally, the response of these arterioles to an
endothelium-independent vasodilator was also assessed.
MATERIALS AND METHODS
MATERIALS
l-Arginine, d-arginine, glycerol, sodium dodecyl sulfate (SDS),
Triton X-100, Tris, sodium acetate, streptozotocin, sodium fluo-
ride, heparin, and sodium nitroprusside were from Sigma-Aldrich
(St. Louis, MO, USA). Aprotinin and leupeptin were from Roche
Applied Sciences (Indianapolis, IN, USA). Nω-hydroxy-nor-
l-arginine (l-OHNA) and S-(2-boronoethyl)-l-cysteine (BEC)
were purchased from EMD Biosciences (San Diego, CA, USA).
[Guanido-14C]l-arginine (52 Ci/mmol) was from Amersham Life
Sciences (Arlington Heights, IL, USA). All other chemicals were
obtained from Fisher Scientific (Houston, TX, USA). Sodium
nitroprusside (10 mM) stock solutions were prepared in saline and
diluted in modified Krebs buffer immediately before use. l-OHNA
(100µM) and BEC (100µM) were dissolved in Krebs buffer just
before use. The composition of the modified Krebs buffer was (in
mM) 118.5 NaCl, 4.7 KCl, 1.4 CaCl2, 1.2 KH2PO4, 1.1 MgSO4,
25.0 NaHCO3, and 11.1 dextrose.
ANIMAL MODEL
Adult male Sprague Dawley rats between 12 and 14 weeks of age
were purchased from Charles River Laboratories (Wilmington,
MA, USA). Diabetes was induced by a single injection of strepto-
zotocin (65 mg/kg, ip) dissolved in sodium citrate (50 mM). Non-
diabetic, control animals were injected with an equivalent volume
of vehicle. Animals were fed standard rat chow, had free access to
drinking water, and were used four weeks after streptozotocin or
vehicle administration. All experiments conform to the Guide for
the Care and Use of Laboratory Animals published by the National
Institutes of Health (NIH Publication No. 85–23, revised 1996)
and were approved by the institutional care and use committee.
HEMODYNAMIC AND METABOLIC MEASUREMENTS AND TISSUE
EXTRACTIONS
Four weeks after the streptozotocin or vehicle administration,
rats were weighed and injected intraperitoneally with ketamine
(100 mg/kg) and zylazine (7.5 mg/kg) (Butler Schein Animal
Health Corporation, Dublin, OH, USA), and a carotid arterial
catheter implanted for blood sample collection and blood pressure
measurement. Blood samples were drawn for immediate deter-
mination of blood glucose (Accu-Chek Compact, Roche Diag-
nostics, Indianapolis, IN, USA), glycated hemoglobin (HbA1c,
DCA 2000+ Analyzer, Bayer, Pittsburgh, PA, USA), and cho-
lesterol (CardioChek PA Analyzer, Polymer Technology Systems,
Inc., Indianapolis, IN, USA). Blood pressure was measured using
a pressure transducer (TSD 104A, Biopac Systems, Santa Bar-
bara, CA, USA) coupled to a polygraph system (Biopac Systems,
Santa Barbara, CA, USA) and a personal computer. Animals were
then heparinized (1000 U/kg, iv) and the thoracic aorta and gra-
cilis anticus muscles removed and placed into ice-cold modified
Krebs buffer or frozen in liquid nitrogen and stored at −70˚C for
later use.
ARGINASE ACTIVITY
Arginase activity was determined by monitoring the formation
of [14C]urea from [guanido-14C]l-arginine, as we previously
reported (Peyton et al., 2009). Blood vessels were sonicated in
Tris buffer (10 mm, pH 7.4) containing Triton X-100 (0.4%), leu-
peptin (10 mg/mL), and aprotinin (10 mg/mL). Lysates (100µg)
were added to an equal volume of Tris buffer (10 mM, pH 7.4)
containing MnCl2 (10 mM) and arginase was activated by heat-
ing for 10 min at 56˚C. The arginase reaction was initiated by
adding Tris buffer containing l-arginine (10 mM) and [guanido-
14C]l-arginine (0.25 Ci), and samples were incubated at 37˚C for
Frontiers in Immunology | Inflammation May 2013 | Volume 4 | Article 119 | 2
Johnson et al. Arginase promotes endothelial dysfunction in diabetes
30 min. Reactions were terminated by adding ice-cold sodium
acetate buffer (250 mM, pH 4.5) containing urea (100 mM).
[14C]Urea was separated from basic amino acids by Dowex chro-
matography and [14C]urea formation determined by scintillation
counting.
ARGINASE EXPRESSION
Arginase expression was determined by quantitative real-time
PCR. Total RNA was isolated from gracilis muscle arterioles using
TRIzol reagent and quantified by absorbance spectroscopy. cDNA
was synthesized with 1µg of RNA using iScript cDNA synthesis
kits (Bio-Rad, Hercules, CA, USA). Quantitative real-time PCR
was carried out using a SYBR Green Supermix (Bio-Rad, Her-
cules, CA, USA) and arginase primers using the Bio-Rad CFX96
system (Sasatomi et al., 2008). Thermal cycling was performed at
95˚C for 10 min followed by 40 cycles at 95˚C for 15 s and 60˚C
for 1 min. Reactions were performed in triplicate. Relative expres-
sion of arginase was analyzed using the delta–delta Ct method and
results normalized with respect to 18S rRNA.
ISOLATED MICROVESSEL EXPERIMENTS
Segments of first-order gracilis muscle arterioles were isolated
by microdissection and cannulated at both ends with glass
micropipettes in a vessel chamber (Living Systems Instrumenta-
tion, Burlington, VT, USA). The vessel chamber was continuously
perfused with Krebs buffer equilibrated with a gas mixture of 14%
O2 and 5% CO2, balanced with N2, in a non-recirculating sys-
tem. For internal diameter measurements, the vessel chamber was
mounted on a stage of an inverted microscope (TS 100-F, Nikon
Instruments, Melville, NY, USA) fitted with a CCD video camera.
The camera was connected to a personal computer equipped with
video dimensioning software (ImagePro Express, Media Cybernet-
ics, Bethesda, MD, USA). Images were collected at 1 frame/s and
stored as digital files for documentation.
To study agonist-induced dilation, the proximal micropipette
was connected to a pressure servo controller (Living Systems
Instrumentation,Burlington,VT,USA) and the distal micropipette
was connected to a closed stopcock to achieve 80 mmHg constant
luminal pressure with no flow. Following a 60 min stabilization
period, peak responses of arterioles to cumulative additions of
sodium nitroprusside (10–1000 nM) were determined by adding
the drug to the superfusion buffer. To study flow-induced dila-
tion, both the proximal and distal micropipettes were connected
to pressure servo controllers and to an inline micro flowmeter
(Living Systems Instrumentation, Burlington, VT, USA). During a
60 min stabilization period, both proximal and distal pressures
were adjusted to 80 mmHg with no luminal flow. In order to
establish graded levels of luminal flow (0–50µL), proximal and
distal pressures were adjusted equally in the opposite direction
maintaining midline pressure at 80 mmHg. In some experiments,
arginase inhibitors or arginine was added to the superfusion buffer
20 min before arterioles were exposed to luminal flow. In order
to limit the possible loss of vascular l-arginine from vessels per-
fused with buffer devoid of l-arginine that may potentially mask
differences between the two groups of animals, the duration of
experiments was restricted to a single flow-response curve per
vessel.
STATISTICS
Results are expressed as mean± SEM. Statistical analyses were per-
formed with the use of a Student’s two-tailed t -test and an analysis
of variance with the Tukey post hoc test when more than two treat-
ment regimens were compared. p-Values <0.05 were considered
statistically significant.
RESULTS
Four weeks after administration of streptozotocin, rats develop
overt diabetes as reflected by elevated fasting blood glucose and
glycated hemoglobin levels compared to vehicle-treated control
animals (Table 1). In addition, body weights of streptozotocin-
diabetic rats were significantly lower than control animals. How-
ever, there was no significant difference in blood pressure, heart
rate, or circulating cholesterol levels between control and diabetic
rats. Vascular arginase activity was markedly increased in diabetic
rats by nearly twofold (Figure 1A). The rise in aortic arginase activ-
ity in diabetic animals was associated with a significant increase in
the expression of both arginase I and II mRNA in gracilis muscle
arterioles (Figure 1B).
Endothelial function was examined in isolated skeletal mus-
cle arterioles. Increases in luminal flow (0–50µL/min) resulted
in progressive vasodilation in arterioles isolated from con-
trol rats (Figure 2). However, flow-mediated vasodilation was
absent in arterioles isolated from diabetic animals. In fact, a
Table 1 | Metabolic and hemodynamic parameters of control and
diabetic rats.
Control Diabetic
Body weight (g) 472±10 288±14*
Blood pressure (mmHg) 122±9 114±12
Heart rate (beats/min) 328±22 302±15
Glucose (mg/dL) 98±8 411±32*
Glycated hemoglobin (%) 3.9±0.1 7.9±0.2*
Cholesterol (mg/dL) 78±6 87±11
Results are means±SEM (n=14–17).
*Statistically significant effect of diabetes (p<0.01).
FIGURE 1 | Diabetes stimulates vascular arginase activity and
expression in rats. Diabetes increases arginase activity in the aorta (A)
and arginase I and II mRNA expression in gracilis muscle arterioles (B).
Results are expressed as mean±SEM (n=4–5). *Statistically significant
effect of diabetes (p<0.05).
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FIGURE 2 | Diabetes abolishes flow-dependent increases in internal
diameter of gracilis muscle arterioles. Arterioles were isolated from
control (open circles) or diabetic (closed circles) rats and exposed to graded
levels of luminal flow. Results are expressed as mean±SEM (n=3–5).
*Statistically significant effect of diabetes (p<0.01).
slight vasoconstrictor effect was noted in diabetic vessels sub-
jected to luminal flow. Since arginase expression was elevated
in gracilis muscle arterioles of diabetic rats, we examined if
arginase was responsible for impairing endothelial function in
these animals. Acute in vitro pretreatment of blood vessels with
the arginase inhibitors, l-OHNA (100µM) or BEC (100µM),
restored flow-induced responses in arterioles from diabetic ani-
mals and abolished differences between the two groups of ani-
mals (Figures 3A,B). Similarly, acute in vitro pretreatment of
vessels with the arginase and NO synthase substrate, l-arginine
(1 mM), reinstated flow-induced dilation in arterioles obtained
from diabetic rats and abrogated the difference between control
and diabetic animals (Figure 4A). In contrast,d-arginine (1 mM),
which is not a substrate for either enzyme, failed to restore flow-
mediated responses in arterioles from diabetic rats (Figure 4B).
Finally, the responsiveness of arteriole smooth muscle to NO was
tested by treating vessels with the NO donor, sodium nitroprus-
side. Sodium nitroprusside dilated arterioles isolated from control
or diabetic animals in a similar concentration-dependent manner
(Figure 5).
DISCUSSION
In the present study, we found that vascular arginase activity is ele-
vated in streptozotocin-treated diabetic rats and this is associated
with a significant increase in the expression of arginase I and II
in gracilis muscle arterioles. In addition, we discovered that lumi-
nal flow-induced vasodilation is severely compromised in gracilis
muscle arterioles isolated from diabetic rats while the vasodila-
tor response to the endothelium-independent agonist, sodium
nitroprusside, is preserved in these vessels. We also found that
acute in vitro pretreatment with arginase inhibitors restores flow-
induced vasodilation and abolishes the difference between control
and diabetic arterioles. Similarly, acute in vitro pretreatment with
the arginase and eNOS substrate, l-arginine, but not the inactive
d isomer, restores flow-mediated vasodilation and eliminates the
difference between the two groups of animals. These findings sug-
gest that increased arginase activity contributes to skeletal muscle
FIGURE 3 | Arginase inhibition restores flow-dependent increases in
internal diameter of gracilis muscle arterioles in diabetes. Arterioles
isolated from control (open circles) or diabetic (closed circles) rats were
treated in vitro with the arginase inhibitors nor-NOHA (100µM) (A) or BEC
(100µM) (B) and then exposed to graded levels of luminal flow. Results are
expressed as mean±SEM (n= 5).
arteriolar endothelial dysfunction in type 1 diabetes by restricting
the availability of l-arginine.
Diabetes was induced in our study by a single injection
of streptozotocin. This glucose moiety selectively destroys the
insulin-producing β-cells of the pancreas leading to rapid insulin-
deficiency and diabetes. This animal model displays polydipsia,
polyuria, hyperglycemia, and weight loss that are similar to the
clinical symptoms found in diabetic patients (Wei et al., 2003;
Akbarzadeh et al., 2007). In agreement with this, we found that
rats treated with streptozotocin develop frank diabetes 4 weeks
after treatment as indicated by raised fasting blood glucose and
glycated hemoglobin concentrations and loss in body weight. The
significant decline in body weight is more pronounced in adult
animals in this model and likely reflects the loss of glucose in the
urine and an inability to metabolize carbohydrates and a shift to
fat metabolism leading to depletion of fat stores (Hoybergs et al.,
2008).
Our finding that vascular arginase activity is increased in type
1 diabetic rats is consistent with recent studies in streptozotocin-
treated rats and mice where elevated arginase activity was reported
in the liver, aorta, kidney, macrophages, retina, and corpora caver-
nosa (Romero et al., 2008, 2012; Morris et al., 2011; Toque et al.,
2011; Sun et al., 2012; Elms et al., 2013). For the first time, we also
show that diabetes induces the expression of both arginase I and
II in gracilis muscle arterioles. This novel observation contrasts
with earlier studies showing that diabetes selectively stimulates
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FIGURE 4 | Effect of arginine on flow-dependent increases in internal
diameter of gracilis muscle arterioles. Arterioles isolated from control
(open symbol) or diabetic (closed symbol) rats were treated in vitro with the
L-arginine (1 mM) (A) or D-arginine (1 mM) (B) and then exposed to graded
levels of luminal flow. Results are expressed as mean±SEM (n=4–5).
*Statistically significant effect of diabetes (p<0.01).
FIGURE 5 | Sodium nitroprusside-mediated increases in internal
diameter of gracilis muscle arterioles. Arterioles isolated from control
(open symbol) or diabetic (closed symbol) rats were exposed to various
concentrations of sodium nitroprusside. Results are expressed as
mean±SEM (n=5).
arginase I or II expression in different tissues, further underscoring
the tissue and vessel-dependent pattern of arginase expression
(see Durante et al., 2006; Morris, 2009). Interestingly, we previ-
ously demonstrated that arginase I and II are also both elevated
in rat gracilis muscle arterioles following the development of salt-
sensitive hypertension, suggesting that arginase I and II are regu-
lated in a coordinate fashion in these vessels (Johnson et al., 2005).
The induction of arginase in diabetes may occur via multiple
mechanisms. Since insulin was recently demonstrated to suppress
plasma arginase activity in diabetic patients, the reduction or lack
of circulating insulin may contribute to the increase in arginase
activity in type 1 diabetes (Kashyap et al., 2008). However, hyper-
glycemia also appears to be involved in the widespread induction
of arginase observed in diabetes as exposure of vascular cells to
high concentrations of glucose triggers a rise in arginase activity
(Durante et al., 2006; Romero et al., 2008). The ability of hyper-
glycemia to augment arginase activity likely occurs via the RhoA
pathway, which can stimulate the induction or activation of both
arginase isoforms (Ming et al., 2004; Romero et al., 2008).
We also found that endothelial function is markedly impaired in
skeletal muscle arterioles from diabetic rats. Endothelial function
was examined using a physiologically relevant stimulus, fluid flow,
in first-order gracilis muscle arterioles. We previously reported
that flow-mediated vasodilation in gracilis muscle arterioles from
normoglycemic rats is completely abolished by eNOS inhibition,
indicating that NO is responsible for flow-induced vasodilation
in these vessels (Johnson and Johnson, 2008). While arterioles
from control rats exhibit pronounced vasodilation in response
to luminal flow, flow-induced vasodilation is absent in arterioles
isolated from diabetic animals, suggesting that endothelial NO
synthesis or bioavailability is dramatically reduced in these ves-
sels. Arterioles from diabetic rats respond as well as arterioles
from control animals to the NO donor, sodium nitroprusside,
indicating that the sensitivity of arteriolar smooth muscle to NO
is unchanged in diabetic animals. Our finding that gracilis mus-
cle arterioles from streptozotocin-treated diabetic rats display a
modest vasoconstrictor response to flow has also been reported
in mesenteric arteries from these animals and may be linked to
diminished NO production (Tribe et al., 1998). To test whether
arginase contributes to impaired endothelial function in type 1
diabetes, we employed two distinct arginase inhibitors, l-OHNA
and BEC, which are highly potent inhibitors of arginase I and
II (Christianson, 2005). We found that acute pretreatment with
either l-OHNA or BEC restores flow-induced dilation in arterioles
from diabetic rats to levels seen in vessels from control animals.
Taken in conjunction with our findings that vascular arginase I
and II expression are increased in diabetic arterioles, these results
suggest that arginase contributes to gracilis muscle arteriolar NO
dysfunction in type 1 diabetes. Our current experimental findings
build on previous work in the vasculature of the heart, retina, and
corpora cavernosa (Romero et al., 2008, 2012; Toque et al., 2011)
and are also supported by a recent clinical study showing arginase
inhibition markedly improves endothelium-dependent vasodila-
tion in the forearm of patients with type 2 diabetes and coronary
artery disease (Shemyakin et al., 2012). Thus, arginase-mediated
endothelial dysfunction may be a characteristic feature of diabetes
that encompasses many vascular beds.
Our finding that arginase inhibition restores endothelium-
dependent vasodilation of skeletal muscle arterioles from dia-
betic animals suggests that arginase may modulate l-arginine
availability for NO synthesis in diabetes. Consideration of the
enzyme kinetics for arginase and eNOS, indicates that arginase
can effectively compete with eNOS for substrate l-arginine
(Wu and Morris, 1998). Consistent with a role for arginase in
depleting substrate for eNOS, vascular l-arginine concentrations
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are significantly reduced in streptozotocin-treated diabetic rats
(Pieper and Dondlinger, 1997). Moreover, we showed that acute
administration of l-arginine mimics the effect of arginase inhi-
bition. l-Arginine restores flow-induced vasodilation in arterioles
from diabetic rats whereas the inactive isomer, d-arginine, has
no effect. The induction of vascular arginase and the subsequent
depletion of l-arginine may also explain the ability of exogenously
administered l-arginine to restore endothelial function and NO
synthesis in both chemical and genetic animal models of type 1 dia-
betes (Pieper and Dondlinger, 1997; Pieper et al., 1997; Kohli et al.,
2004). Furthermore, arginase-mediated decreases in intracellular
l-arginine may negatively impact endothelial function by sensitiz-
ing endothelial cells to the endogenous eNOS inhibitor, asymmet-
ric dimethylarginine, which is elevated in streptozotocin-treated
rats (Lin et al., 2002). Finally, arginase-mediated depletion of argi-
nine may further compromise endothelial function in diabetes by
uncoupling eNOS (Kim et al., 2009).
The ability of arginase to inhibit endothelial function in skele-
tal muscle arterioles in diabetes is of pathological significance.
Skeletal muscle arterioles contribute greatly to peripheral resis-
tance and consequently are major determinants of blood pressure.
Thus, arginase-mediated impairment of skeletal muscle arteriolar
function may contribute to the development of hypertension in
diabetes. Although blood pressure not increased four weeks after
streptozotocin administration in our study, a longer duration of
diabetes is associated with the development of hypertension in
this animal model. Recently, El-Bassossy et al. (2012) reported
that diabetic rats develop a significant increase in systolic and
diastolic blood pressure 8 weeks following streptozotocin treat-
ment. Notably, administration of arginase inhibitors for the last
6 weeks significantly reduced the developed elevation in diastolic
blood pressure in these animals, illustrating a role for arginase
in diabetes-associated hypertension. Since skeletal muscle rep-
resents a major site of insulin-dependent glucose uptake and
utilization, arginase-mediated endothelial dysfunction may limit
skeletal muscle perfusion and exacerbate hyperglycemia in dia-
betes. In support of this proposal, arginase inhibition reduces
the rise in serum glucose and advanced glycation end products
in type 1 diabetic rats (El-Bassossy et al., 2012), while arginase
II deletion improves glucose tolerance and insulin sensitivity
in type 2 diabetic mice (Ming et al., 2012). Thus, arginase-
mediated endothelial dysfunction of skeletal muscle arterioles may
promote the vascular and metabolic derangements observed in
diabetes.
In conclusion, the present study identifies arginase as a criti-
cal mediator of skeletal muscle arteriolar endothelial dysfunction
in diabetes. Flow-induced vasodilation is abolished in gracilis
muscle arterioles of streptozotocin-treated rats and this is asso-
ciated with an increase in arteriolar arginase I and II expression.
Moreover, pretreatment of blood vessels with arginase inhibitors
or l-arginine fully restores flow-induced vasodilation in arteri-
oles from diabetic rats. These results provide novel insight into
the mechanism by which skeletal muscle arteriolar function is
compromised in diabetes, and establishes arginase as a potential
therapeutic target in treating vascular and metabolic disorders in
diabetes.
ACKNOWLEDGMENTS
This work was supported by grants from the National Institutes of
Health National Heart, Lung, and Blood Institute (Grants R01-HL
059976, R01-HL074966, and R01 HL076187), the Juvenile Dia-
betes Research Foundation, and the American Heart Association
Midwest Affiliate (0855715G) and South Central Affiliates (BGIA
0865241F).
REFERENCES
Akbarzadeh, A., Norouzian, D.,
Mehrabi, M. R., Jamshidi, S.,
Farhangi, A., Allah Verdi, A., et al.
(2007). Induction of diabetes by
streptozotocin in rats. Indian J. Clin.
Biochem. 22, 60–64.
Beckman, J. A., Creager, M. A., and
Libby, P. (2002). Diabetes and ath-
erosclerosis: epidemiology, patho-
physiology, and management. JAMA
286, 2570–2581.
Beleznai, T., Feher, A., Spielvogel, D.,
Lansman, S. L., and Bagi, Z. (2011).
Arginase I contributes to dimin-
ished coronary arteriolar dilation in
patients with diabetes. Am. J. Phys-
iol. Heart Circ. Physiol. 300, H777–
H783.
Bolz, S. S., de Wit, C., and Pohl,
U. (1999). Endothelium-derived
hyperpolarizing factor but not NO
reduces smooth muscle Ca2+ dur-
ing acetylcholine-induced dilation
of microvessels. Br. J. Pharmacol.
128, 124–134.
Christianson, D. W. (2005). Arginase:
structure, mechanism, and physi-
ological role in male and female
sexual arousal. Acc. Chem. Res. 38,
191–201.
Demougeot, C., Prigent-Tesssier,
A., Marie, C., and Berthelot, A.
(2005). Arginase inhibition reduced
endothelial dysfunction and blood
pressure rising in spontaneously
hypertensive rats. J. Hypertens. 23,
971–978.
Dizikes, G. J., Grody, W. W., Kern, R. M.,
and Cederbaum, S. D. (1986). Isola-
tion of human liver arginase cDNA
and demonstration of nonhomol-
ogy between the two human arginase
genes. Biochem. Biophys. Res. Com-
mun. 141, 53–59.
Duby, J. J., Campbell, R. K., Setter, S.
M., White, J. R., and Rasmussen, K.
A. (2004). Diabetic neuropathy: an
intensive review. Am. J. Health Syst.
Pharm. 61, 160–173.
Durante, W., Johnson, F. K., and John-
son, R. A. (2007). Arginase: a criti-
cal regulator of nitric oxide synthe-
sis and vascular function. Clin. Exp.
Pharmacol. Physiol. 34, 906–911.
Durante, W., Johnson, F. K., Johnson,
R. A., Liu, X. M., Ensenat, D., and
Peyton, K. J. (2006). Hyperglycemia
stimulates vascular arginase activity.
FASEB J. 20, A727, abstr. 465.5.
Durante, W., Sen, A. K., and Suna-
hara, F. A. (1988). Impairment
of endothelial-dependent relaxation
in aortae from spontaneously dia-
betic rats. Br. J. Pharmacol. 94,
463–468.
El-Bassossy, H. M., El-Fawal, R.,
and Fahmy, A. (2012). Arginase
inhibition alleviates hyperten-
sion associated with diabetes:
effect on endothelial dependent
relaxation and NO produc-
tion. Vascul. Pharmacol. 57,
194–200.
Elms, S. C., Toque, H. A., Rojas, M.,
Xu, Z., Caldwell, R. B., and Caldwell,
R. W. (2013). The role of arginase
I in diabetes-induced retinal vascu-
lar dysfunction in mouse and rat
models of diabetes. Diabetologia 56,
654–662.
Forstermann, U., and Sessa, W.C.
(2012). Nitric oxide synthases: reg-
ulation and function. Eur. Heart J.
33, 829–837.
Goldberg, R. B. (2003). Cardiovas-
cular disease in patients who
have diabetes. Cardiol. Clin. 21,
399–413.
Gronros, J., Jung, C., Lundberg, J. O.,
Cerrato,R.,Ostenson,C. G., and Per-
now, J. (2011). Arginase inhibition
restores in vivo coronary microvas-
cular function in type 2 diabetic rats.
Am. J. Physiol. Heart Circ. Physiol.
300, H1174–H1181.
Hattori, Y., Kawasaki, H., Abe, K.,
and Kanno, M. (1991). Super-
oxide dismutase recovers altered
endothelium-dependent relaxation
in diabetic rat aorta. Am. J. Physiol.
261, H1086–H1094.
Hoybergs, Y. M. J. J., Bierman, R. L. V.,
and Meert, T. F. (2008). The impact
of body weight and body condition
on behavioral testing for painful dia-
betic neuropathy in the streptozo-
tocin rat model. Neurosci. Lett. 436,
13–18.
Johnson, F. K., Johnson, R. A., Pey-
ton, K. J., and Durante, W. (2005).
Arginase inhibition restores arteri-
olar endothelial function in Dahl
rats with salt-induced hypertension.
Am. J. Physiol. Regul. Integr. Comp.
Physiol. 288, R1057–1062.
Frontiers in Immunology | Inflammation May 2013 | Volume 4 | Article 119 | 6
Johnson et al. Arginase promotes endothelial dysfunction in diabetes




in resistance vessels. Shock 29,
526–530.
Johnson, M. T., Creager, S. J., Scales,
K. M., Cusco, J. A., Lee, B.
K., and Creager, M. A. (1993).
Impaired endothelium-dependent
vasodilation in patients with insulin-
dependent diabetes mellitus. Circu-
lation 88, 2510–2516.
Johnson, R. A., Durante, W., Craig, T.,
Peyton, K. J., Myers, J. G., Stewart, R.
M., et al. (2010). Vascular arginase
contributes to arteriolar endothe-
lial dysfunction in a rat model of
hemorrhagic shock. J. Trauma 69,
384–391.
Kannel, W. B., and McGee, D. L. (1979).
Diabetes and cardiovascular disease:
the Framingham study. JAMA 241,
2035–2038.
Kashyap, S. R., Lara, A., Zhang, R.,
Park, Y. M., and Defronzo, R.
A. (2008). Insulin reduces plasma
arginase activity in type 2 diabetic
patients. Diabetes Care 31, 134–139.
Kikkawa, R., Koya, D., and Haneda,
M. (2003). Progression of diabetic
nephropathy. Am. J. Kidney Dis. 41,
S19–S21.
Kim, J. H., Bugai, L. J., Oh, Y. J., Bivalac-
qua, T. J., Ryoo, S., Soucy, K. G., et al.
(2009). Arginase inhibition restores
NOS coupling and reverses endothe-
lial dysfunction and vascular stiff-
ness in old rats. J. Appl. Physiol. 107,
1249–1257.
Kohli, R., Meininger, C. J., Haynes, T. E.,
Yan, W., Self, J. T., and Wu, G. (2004).
Dietary L-arginine supplementation
enhances endothelial nitric oxide
synthesis in streptozotocin-induced
diabetic rats. J. Nutr. 134, 600–608.
Lin, K. Y., Ito, A., Asagami, T., Tsao, P.
S., Adimoolam, S., Kimoto, M., et al.
(2002). Impaired nitric oxide syn-
thase pathway in diabetes mellitus:
role of asymmetric dimethylargi-
nine and dimethylarginine dimethy-
laminohydrolase. Circulation 106,
987–992.
Loscalzo, J., and Welch, G. (1995). Nitric
oxide and its role in the cardiovascu-
lar system. Prog. Cardiovasc. Dis. 38,
87–104.
Ming, X.-F., Barandier, C., Viswamb-
haran, H., Kwak, B. R., Mach,
F., Mazzolai, L., et al. (2004).
Thrombin stimulates human
endothelial arginase enzymatic
activity via the RhoA/ROCK path-
way: implications for atherosclerotic
endothelial dysfunction. Circulation
110, 3708–3714.
Ming, X.-F., Rajapakse, A. G., Yepuri,
G., Xiong, Y., Carvas, J. M., Ruffieux,
J., et al. (2012). Arginase II pro-
motes macrophage inflammatory
responses through mitochondrial
reactive oxygen species, contributing
to insulin resistance and atherogen-
esis. J. Am. Heart Assoc. 1, e000992.
Morris,S. M. Jr. (2009). Recent advances
in arginine metabolism: roles and
regulation of the arginases. Br. J.
Pharmacol. 157, 922–930.
Morris, S. M. Jr., Gao, T., Cooper, T.
K., Kepka-Lenhart, D., and Awad,
A. S. (2011). Arginase-2 mediates
diabetic renal injury. Diabetes 60,
3015–3022.
Nitenberg, A., Valensi, P., Sachs, R.,
Dali, M., Aptecar, E., and Attali,
J. (1993). Impairment of coronary
vascular reserve and acetylcholine-
induced coronary vasodilation in
diabetic patients with angiographi-
cally normal coronary arteries and
normal left ventricular systolic func-
tion. Diabetes 42, 1017–1025.
Peyton, K. J., Ensenat, D., Azam, M.
A., Keswani, A. N., Kannan, S.,
Liu, X.-M., et al. (2009). Arginase
promotes neointima formation in
rat injured carotid arteries. Arte-
rioscler. Thromb. Vasc. Biol. 29,
488–494.
Pieper, G. M., and Dondlinger,
L. A. (1997). Plasma and
vascular tissue arginine are
decreased by diabetes: acute
arginine supplementation restores
endothelium-dependent relaxation
by augmenting cGMP produc-
tion. J. Pharmacol. Exp. Ther. 283,
684–691.
Pieper, G. M., Siebeneich, W., Moore-
Hilton, G., and Roza, A. M. (1997).
Reversal by L-arginine of a dysfunc-
tional arginine/nitric oxide pathway
in the endothelium of the genetic
diabetic BB rat. Diabetologia 40,
910–915.
Porta, M., and Bandello, F. (2002). Dia-
betic retinopathy: a clinical update.
Diabetologia 45, 1617–1634.
Romero, M. J., Iddings, J. A., Platt, D. H.,
Ali,M. I.,Cederbaum,S. D.,Stepp,D.
W., et al. (2012). Diabetes-induced
vascular dysfunction involves
arginase I. Am. J. Physiol. Heart Circ.
Physiol. 302, H159–H166.
Romero, M. J., Platt, D. H., Taw-
fik, H. E., Labazi, M., El-Remessy,
A. B., Bartoli, M., et al. (2008).
Diabetes-induced coronary vascu-
lar dysfunction involves increased
arginase activity. Circ. Res. 102,
95–102.
Ryoo,S.,Gupta,G.,Benjo,A.,Lim,H. K.,
Camara, A., Sikka, G., et al. (2008).
Endothelial arginase II. A novel tar-
get for the treatment of atheroscle-
rosis. Circ. Res. 102, 923–932.
Sasatomi, K., Hiragata, S., Miyazato,
M., Chancellor, M. B., Morris, S.
M. Jr., and Yoshimura, N. (2008).
Nitric oxide-mediated suppression
of detrusor overactivity by arginase
inhibitor in rats with chronic
spinal cord injury. Urology 72,
696–700.
Shemyakin, A., Kovamees, O., Rafnsson,
A., Bohm, F., Svenarud, P., Setter-
gren, M., et al. (2012). Arginase inhi-
bition improves endothelial func-
tion in patients with coronary artery
disease and type 2 diabetes. Circula-
tion 126, 2943–2950.
Sun, C., Sun, L., Ma, H., Peng, J., Zhen,
Y., Duan, K., et al. (2012). The phe-
notype and functional alterations of
macrophages in mice with hyper-
glycemia for long term. J. Cell. Phys-
iol. 227, 1670–1679.
Tesfamariam, B., and Cohen, R. A.
(1992). Free radicals mediate
endothelial cell dysfunction caused
by elevated glucose. Am. J. Physiol.
263, H321–H326.
Toque, H. A., Tostes, R. C., Yao, L.,
Xu, Z., Webb, R. C., Caldwell, R. B.,
et al. (2011). Arginase II deletion
increases corpora cavernosa relax-
ation in diabetic mice. J. Sex. Med.
8, 722–733.
Tribe, R. M., Thomas, C. R., and Poston,
L. (1998). Flow-induced dilation in
isolated resistance arteries from con-
trol and streptozotocin-diabetic rats.
Diabetologia 41, 34–39.
Vockley, J. G., Jenkinson, C. P., Shukla,
H., Kern, R. M., Grody, W. W., and
Cederbaum, S. D. (1996). Cloning
and characterization of the human
type II arginase gene. Genomics 2,
118–123.
Wei, M., Ong, L., Smith, M. T., Ross,
F. B., Schmid, K., Hoey, A. J.,
et al. (2003). The streptozotocin-
diabetic rat model as a model
of the chronic complications of
human diabetes. Heart Lung Circ. 12,
44–50.
Winer, N., and Sowers, J. R. (2004).
Epidemiology of diabetes. J. Clin.
Pharmacol. 44, 397–405.
Wu, G., and Morris, S. M. Jr. (1998).
Arginine metabolism: nitric oxide
and beyond. Biochem. J. 336, 1–7.
Xu, W., Kaneko, F. T., Zheng, S.,
Comhair, S. A., Janocha, A. J., Gog-
gans, T., et al. (2004). Increased
arginase II and decreased NO
synthesis in endothelial cells of
patients with pulmonary hyperten-
sion. FASEB J. 18, 1746–1748.
Conflict of Interest Statement: The
authors declare that the research was
conducted in the absence of any com-
mercial or financial relationships that
could be construed as a potential con-
flict of interest.
Received: 20 March 2013; paper pend-
ing published: 08 April 2013; accepted:
04 May 2013; published online: 20 May
2013.
Citation: Johnson FK, Johnson RA, Pey-
ton KJ, Shebib AR and Durante W (2013)
Arginase promotes skeletal muscle arte-
riolar endothelial dysfunction in dia-
betic rats. Front. Immunol. 4:119. doi:
10.3389/fimmu.2013.00119
This article was submitted to Frontiers in
Inflammation, a specialty of Frontiers in
Immunology.
Copyright © 2013 Johnson, Johnson, Pey-
ton, Shebib and Durante. This is an
open-access article distributed under the
terms of the Creative Commons Attribu-
tion License, which permits use, distrib-
ution and reproduction in other forums,
provided the original authors and source
are credited and subject to any copy-
right notices concerning any third-party
graphics etc.
www.frontiersin.org May 2013 | Volume 4 | Article 119 | 7
